Reference : Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is a...
Scientific journals : Letter to the editor
Human health sciences : Cardiovascular & respiratory systems
http://hdl.handle.net/2268/254919
Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels
English
SIBILLE, Anne mailto [Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie >]
HENKET, Monique mailto [Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique de l'asthme >]
Corhay, Jean-Louis mailto [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
Louis, Renaud mailto [Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie >]
DUYSINX, Bernard mailto [Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Oncologie thoracique >]
2020
Acta Oncologica
Taylor and Francis Ltd
59
3
257-259
Yes (verified by ORBi)
International
0284186X
1651226X
[en] Letter
[en] [No abstract available]
http://hdl.handle.net/2268/254919
10.1080/0284186X.2019.1695063

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
SIBILLE 2019_Clinical benefit to programmed_Acta oncologica_OCR.pdfAuthor postprint315.39 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.